Filing Flows

Filing Flows › 8-K events › Lifecore Biomedical

Lifecore Biomedical: other events

Form 8-K filed Nov 5, 2026 · items 8.01

What the filing says

As previously disclosed, on September 27, 2026, Lifecore Biomedical, Inc. (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Lifecore Inc. (“Parent”) and Hazel Merger Sub, Inc. (“Merger Sub”) providing for the merger of Merger Sub with and into the Company (the “Merger”), with th

Read the filing on SEC EDGAR →

What usually followsAcross 44,881 8-Ks reporting Item 8.01 (other events) in our universe, the stock's median move the next session was +0.1% (typical size ±1.5%, up 52% of the time); over the following 21 sessions, +1.1%. Every item ranked →

Lifecore Biomedical at a glance

Latest quarterQ1 FY27
Revenue$25.3M
Revenue Y/Y-19%
Operating margin-3.5%
IndustryPharmaceutical Preparations

Lifecore Biomedical, Q1 FY27: revenue $25.3M (-19% year over year), operating margin -3.5%. The chart follows the revenue to costs, profit and cash.

Lifecore Biomedical: every quarter, Q/Q and Y/Y, holders and guidance →

Other recent mergers and acquisitions

Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.